Global pharmaceutical company Cadila Healthcare on Friday posted a 11 percent increase in its net profit at Rs 388.7 crore for the fourth quarter ended March as compared to Rs.350.4 crore in the year-ago period, on account of robust sales.

Total income rose seven percent to Rs.2,449 crore in the quarter under review from Rs.2,288 crore in the corresponding period last year, it said in a filing at Bombay Stock Exchange (BSE).

The company said its formulation business in India grew by 11 percent during last fiscal on the back of launch of more than 40 new products, including line extensions, while in emerging markets, it grew 17 percent.

For 2015-16, the medicine maker reported a 32 percent rise in its net profit at Rs.1,523 crore from Rs.1,151 crore in 2014-15.

Its formulation business in the US was the largest contributor to the consolidated revenues, growing 19 percent.

Company’s scrip on Friday closed at Rs.326.55, down 2.05 percent on BSE from previous close.